Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant

Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant.

Viibryd (vilazodone) inhibits serotonin reuptake like SSRIs...plus it's also a partial serotonin agonist.

The company hoped Viibryd would be more effective than SSRIs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote